Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 160

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 160
---
 of any transaction between us, and investigating any alleged fraud;

reviewing and discussing with our management our major financial risk exposures and the steps taken to monitor and control such exposures, including the use of any financial derivatives and hedging activities;

reviewing, discussing and investigating any alleged fraud involving our management or employees in relation to the internal controls, including our management's response to any allegations of fraud;

reviewing the financial reporting of any transaction between us and any officer, director or other "related party" or any entity in which any such person has a financial interest;

recommending an auditor for nomination and the auditors compensation to the Board, overseeing the work of the auditors, establishing communication with the auditors, reviewing the independence of the auditor, the audit plan, the performance of the auditors, and the results of the external audit and the report thereon;

<div align='center'>116</div>

monitoring and periodically reviewing our corporate policies and associated procedures, and hiring policies; and

providing broad oversight of our financial, risk and control related activities.

The Audit Committee has unrestricted access to all information regarding the Company and all our directors, officers and employees and will be directed to cooperate as requested by the Audit Committee. The Audit Committee has the authority to retain, at our expense, outside legal, financial and other advisors, consultants and experts, to assist the Audit Committee in fulfilling its duties and responsibilities. The Audit Committee also has the authority to communicate directly with the auditors and, if applicable, our internal auditors.

Pre-Approval Policies and Procedures

The Audit Committee will pre-approve all non-audit services to be provided to us by its external auditors. The Audit Committee may delegate to one or more of its members the authority to pre-approve non-audit services but preapproval by such member or members so delegated shall be presented to the full Audit Committee at its first scheduled meeting following such pre-approval.

External Auditor Service Fees

The aggregate fees billed by the Company's external auditors in the years ended December 31, 2024 and 2023 are set out below:

| Financial Year       
 Ending               | Audit Fees(1) 
           ($) | Audit-Related 
   Fees(2) ($) | Tax Fees(3) 
         ($) | All Other Fees(4) 
               ($) |
| December 31, 2024(5) |       168,000 |             - |           - |                 - |
| December 31, 2024(6)